Ocuphire Pharma Results Presentation Deck slide image

Ocuphire Pharma Results Presentation Deck

RM 16 Secondary Endpoint: Mean Pupil Diameter Over Time by Mydriatic Agent Nyxol Reduced Pupil Diameter With All Mydriatic Agents; More Rapidly with Phenylephrine as Expected Pupil Diameter (mm) 9 8 LO 4 3 Mydriatic L -1 1 Max pupil dilation, Treatment p<0.0001 T Phenylephrine p<0.0001 -Nyxol n=56 T p<0.0001 I I p<0.0001 p<0.0001 MIRA-2 Phase 3 Trial Study Eye, mITT Population Placebo n=55 4 0 0.5 1 1.5 2 3 Time Post-Treatment with Nyxol/Placebo (Hours) p<0.0001 H Source: MIRA-2 TLR table #14.2.2.3 (mITT). Standard Error bars are shown. 6 Pupil Diameter (mm) 9 8 4 3 ± Max pupil dilation, Treatment Mydriatic Tropicamide or Paremyd p<0.0001 p<0.0001 X p<0.0001 -Nyxol n=38 -1 0 0.5 1 1.5 2 T p<0.0001 p<0.0001 Placebo n=36 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) p<0.0001 +4 Ocuphire PHARMA
View entire presentation